secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2021-12-20T23:59:59+00:00
Accession:  0001558370-21-016940
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Kala Pharmaceuticals promotes Todd Bazemore to President and COO, effective Dec 16, 2021
--------------------------------------------------------------------------------

- Todd Bazemore, COO since Nov 2017, appointed President and COO effective December 16, 2021.
- Mark Iwicki remains CEO and Chairman but no longer serves as President of the Company.
- No changes to Bazemore's compensation or compensatory plans in connection with the promotion.
- Bazemore has served on Pulmatrix's board of directors since October 2020.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000155837021016940/0001558370-21-016940-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000155837021016940/kala-20211216x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-21-016940

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer